Literature DB >> 17164133

Epoxyeicosatrienoic acids, cell signaling and angiogenesis.

Ingrid Fleming1.   

Abstract

Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases the expression of which is determined by hemodynamic and pharmacological stimuli as well as by hypoxia. The activation of CYP epoxygenases in endothelial cells is an important step in the vasodilatation that has been attributed to the endothelium-derived hyperpolarizing factor. However, in addition to regulating vascular tone EETs modulate several signaling cascades and affect cell proliferation, cell migration and angiogenesis. These include the epidermal growth factor receptor, tyrosine kinases and phosphatases, mitogen-activated protein kinases, protein kinase A, cyclooxygenase-2 and several transcription factors. To-date however, the importance of EETs in vascular homeostasis has been largely underestimated because of the labile nature of the EET-forming enzymes in cell culture. This also means that the contribution of CYP-derived products in the vast majority of the experimental models based on cell culture systems to address topics related to vascular signaling/homeostasis and angiogenesis has been overlooked.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17164133     DOI: 10.1016/j.prostaglandins.2006.05.003

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  69 in total

Review 1.  Targeting epoxides for organ damage in hypertension.

Authors:  John D Imig
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

2.  The ω-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down-regulation.

Authors:  Pei H Cui; Nenad Petrovic; Michael Murray
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

3.  Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.

Authors:  Chen Chen; Xin Wei; Xiaoquan Rao; Jun Wu; Shenglan Yang; Fuqiong Chen; Ding Ma; Jianfeng Zhou; Ryan T Dackor; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2010-10-28       Impact factor: 4.030

Review 4.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

5.  Development of a high throughput cell-based assay for soluble epoxide hydrolase using BacMam technology.

Authors:  Wensheng Xie; Xiaoyan Tang; Quinn Lu; Robert S Ames; Steven J Ratcliffe; Hu Li
Journal:  Mol Biotechnol       Date:  2010-07       Impact factor: 2.695

6.  Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury.

Authors:  Xiaojing Chen; Xiaoqi Chen; Xiaojiang Huang; Chuan Qin; Yongkang Fang; Yang Liu; Guibing Zhang; Dengji Pan; Wei Wang; Minjie Xie
Journal:  Mol Neurobiol       Date:  2015-02-10       Impact factor: 5.590

7.  Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.

Authors:  Hsing-Ju Tsai; Sung Hee Hwang; Christophe Morisseau; Jun Yang; Paul D Jones; Takeo Kasagami; In-Hae Kim; Bruce D Hammock
Journal:  Eur J Pharm Sci       Date:  2010-03-30       Impact factor: 4.384

Review 8.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

9.  Class A scavenger receptor-mediated macrophage adhesion requires coupling of calcium-independent phospholipase A(2) and 12/15-lipoxygenase to Rac and Cdc42 activation.

Authors:  Dejan M Nikolic; Ming C Gong; John Turk; Steven R Post
Journal:  J Biol Chem       Date:  2007-09-15       Impact factor: 5.157

10.  Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.

Authors:  Jeffrey J Iliff; Nabil J Alkayed
Journal:  Future Neurol       Date:  2009-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.